Sage Therapeutics rejects Biogen's $469M buyout offer. CEO Barry Greene and board seek alternatives, with Goldman Sachs ...

Eisai and Biogen scored an approval for once-monthly IV maintenance dosing of their Alzheimer’s drug Leqembi, as part of what ...

Replacing fossil fuels with green hydrogen depends on creating demand by making it price competitive, as buyers are unwilling to pay "green premiums", Fortescue Energy CEO Mark Hutchinson told Reuters ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

SAN FRANCISCO (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its ...

The second example is Watches of Switzerland (OTCPK:WOSGF), which trades for 13x EV/FCF despite being Rolex’s key partner in the UK and US and having a long runway for double-digit growth.

Moreover, Biogen’s valuation appears to be fairly priced at current levels, as indicated by a Discounted Cash Flow analysis projecting revenues through 2033. While the company has potential ...

Biogen Inc. (NASDAQ:BIIB), a leader in biotechnology, announced the appointment of Sean Godbout as Vice President, Chief Accounting Officer & Global Corporate Controller, effective March 1, 2025 ...

Eisai and Biogen’s antibody is currently infused every two weeks at hospitals and dedicated infusion sites. Image credit: Shutterstock/ AtlasStudio. Eisai and Biogen are one step away from deploying a ...